Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorUniversity of California, Los Angeles
About this trial
This pilot pre-post trial will address a gap in knowledge related to addressing modifiable risk factors for cardiometabolic disease through treating residual insomnia, sleep difficulties that remain after successful treatment of another condition, in the context of PTSD in understudied older adults. This study provides a non-medication treatment for PTSD called Cognitive Processing Therapy (CPT) followed by a non-medication sleep education and treatment program (Cognitive Behavioral Therapy for Insomnia, CBT-I) for sleep problems that remain after completing PTSD treatment in older adults with PTSD. The aims of this project are to evaluate 1) the added benefits of treating residual insomnia on sleep and PTSD symptoms; 2) the added benefits of treating residual insomnia following CPT on cardiometabolic risk biomarkers and quality of life; and 3) the durability of the sleep, PTSD, cardiometabolic and quality of life benefits of treating residual insomnia following CPT at 6-month follow-up in older adults with PTSD.
Eligibility criteria
Qualifiers
Community-dwelling Veterans aged 50 years and older
Received care from a Veterans Health Administration (VHA) facility in the prior year
Diagnosis of PTSD
Diagnosis of insomnia disorder
Disqualifiers
Active substance use or in recovery with less than 90 days of sobriety
Too ill to engage in the study procedures (e.g., unable to attend the in-person meetings)
Unable to self-consent to participate
Unstable housing (as this will impact the research team's ability to retrieve costly and difficult to replace monitoring equipment)
Trial design
Treatments tested in this trial
- Behavioral Sleep Education Intervention
Treatment groups
167 Participants
are divided into 1 treatment groupSponsors and collaborators
University of California, Los Angeles
Lead sponsor
VA Office of Research and Development
Collaborator
Source ClinicalTrials.gov